Moderna’s respiratory syncytial virus (RSV) vaccine mRESVIA has been approved by the Medicines and Healthcare products ...
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved an mRNA respiratory syncytial virus (RSV) ...
The pandemic's volatility affected all public companies, but some saw their business deeply transformed. Here's how three of ...
A study found that around 4 months after vaccination, people who received the RSV vaccine had a 79% reduction in their risk ...
"The MHRA's authorization of our RSV vaccine is an important milestone for Moderna's efforts toward respiratory disease preparedness," said Stéphane Bancel, Chief Executive Officer of Moderna. "Our ...
Arbutus Biopharma and Genevant Sciences are broadening the scope of their patent infringement claims against Moderna with ...
The vaccine, manufactured by US pharmaceutical giant Moderna, was found to slash the risk of severe illness from respiratory ...
mRESVIA ® is Moderna's second approved product in the UK CAMBRIDGE, MA / ACCESS Newswire / February 28, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Medicines and Healthcare ...
Moderna (MRNA) announced that the Medicines and Healthcare products Regulatory Agency in the UK has granted marketing authorization for mRESVIA, indicated for active immunization for the prevention of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback